Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Specimen Handling 113Magnetic Resonance Spectroscopy 113Cyclophosphamide 106pembrolizumab 82Radiotherapy 79Nivolumab 68Cisplatin 67fludarabine 64Carboplatin 59Biopsy 54Standard of Care 46Radiosurgery 43Gemcitabine 43Paclitaxel 42Dexamethasone 41Rituximab 37Radiation 37Doxorubicin 37Blood Specimen Collection 37Cytarabine 36Bevacizumab 35venetoclax 34fludarabine phosphate 33Surveys and Questionnaires 32Temozolomide 31Radiotherapy, Intensity-Modulated 31Capecitabine 31Practice Guidelines as Topic 28Etoposide 28Oxaliplatin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × mirvetuximab soravtansine × 30 days × Clear all
NCT05887609 2026-06-04

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

University of Colorado, Denver

Phase 2 Recruiting
53 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03835819 2026-06-01

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
18 enrolled 17 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡